Abstract
Didemnin B was administered to 24 women with recurrent squamous cell cervical carcinoma. The initial dose was 4.2 mg/m2, intravenously, repeated every 28 days. Twenty-three patients were evaluable for toxicity and twenty-one for response. Toxicity was mild, consisting mainly of nausea and vomiting. There were no objective responses; 43% had stable disease for at least 3 months. Didemnin B, when given in this dosage schedule, appears to have minimal effect against this tumor.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Squamous Cell / drug therapy*
-
Depsipeptides*
-
Drug Evaluation
-
Female
-
Humans
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Peptides, Cyclic / adverse effects
-
Peptides, Cyclic / therapeutic use*
-
Treatment Outcome
-
Uterine Cervical Neoplasms / drug therapy*
Substances
-
Antineoplastic Agents
-
Depsipeptides
-
Peptides, Cyclic
-
didemnins